These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25940912)

  • 1. Targeting interferons in systemic lupus erythematosus: current and future prospects.
    Mathian A; Hie M; Cohen-Aubart F; Amoura Z
    Drugs; 2015 May; 75(8):835-46. PubMed ID: 25940912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
    Kalunian KC
    Lupus; 2016 Sep; 25(10):1097-101. PubMed ID: 27497254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interferon alpha treatment in SLE.
    Kirou KA; Gkrouzman E
    Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.
    Greth W; Robbie GJ; Brohawn P; Hultquist M; Yao B
    Immunotherapy; 2017 Jan; 9(1):57-70. PubMed ID: 28000522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon α-targeted therapy.
    Hanaoka H; Takeuchi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):181-8. PubMed ID: 23994795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus.
    Welcher AA; Boedigheimer M; Kivitz AJ; Amoura Z; Buyon J; Rudinskaya A; Latinis K; Chiu K; Oliner KS; Damore MA; Arnold GE; Sohn W; Chirmule N; Goyal L; Banfield C; Chung JB
    Arthritis Rheumatol; 2015 Oct; 67(10):2713-22. PubMed ID: 26138472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E; Furie R
    Immunotherapy; 2020 Apr; 12(5):275-286. PubMed ID: 32237942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I interferon blockade in systemic lupus erythematosus: where do we stand?
    Lauwerys BR; Ducreux J; Houssiau FA
    Rheumatology (Oxford); 2014 Aug; 53(8):1369-76. PubMed ID: 24344319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
    Yao Y; Higgs BW; Richman L; White B; Jallal B
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
    Chyuan IT; Tzeng HT; Chen JY
    Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned.
    Jones SA; Morand EF
    Drugs; 2024 Jun; 84(6):625-635. PubMed ID: 38807010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus.
    Mathian A; Amoura Z; Adam E; Colaone F; Hoekman MF; Dhellin O; Vandepapelière P; Haroche J; Piette JC; Lebon P; Grouard-Vogel G
    Ann Rheum Dis; 2011 Jun; 70(6):1138-43. PubMed ID: 21389044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I interferon antagonists in clinical development for lupus.
    Paredes JL; Niewold TB
    Expert Opin Investig Drugs; 2020 Sep; 29(9):1025-1041. PubMed ID: 32700979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
    Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
    Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab.
    Maurer B; Bosanac I; Shia S; Kwong M; Corpuz R; Vandlen R; Schmidt K; Eigenbrot C
    Protein Sci; 2015 Sep; 24(9):1440-50. PubMed ID: 26099203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus.
    Du P; Xu L; Qiu W; Zeng D; Yue J; Wang S; Huang P; Sun Z
    MAbs; 2015; 7(5):969-80. PubMed ID: 26048268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting interferons and their pathways in systemic lupus erythematosus.
    Chasset F; Arnaud L
    Autoimmun Rev; 2018 Jan; 17(1):44-52. PubMed ID: 29108825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.